Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBV
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Compensated Cirrhosis
Conditions
Compensated Cirrhosis
Trial Timeline
Aug 1, 2018 → Dec 31, 2020
NCT ID
NCT03037151About Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBV
Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBV is a approved stage product being developed by Merck for Compensated Cirrhosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT03037151. Target conditions include Compensated Cirrhosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03037151 | Approved | UNKNOWN |
Competing Products
9 competing products in Compensated Cirrhosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo | Trevena | Phase 2 | 44 |
| Mesenchymal Stem Cell | Rohto Pharmaceutical | Pre-clinical | 23 |
| Mesenchymal stem cell | Rohto Pharmaceutical | Phase 1/2 | 41 |
| telbivudine/LDT600 | Novartis | Approved | 85 |
| Terlipressin acetate + Serelaxin (RLX030) | Novartis | Phase 2 | 52 |
| Aliskiren + Placebo | Novartis | Phase 3 | 77 |
| Telbivudine/LDT600A | Novartis | Approved | 85 |
| BMS-986259 | Bristol Myers Squibb | Phase 2 | 51 |
| Albutein 20% | Grifols | Phase 3 | 74 |